A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Epirubicin; Fluorouracil; Oxaliplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- 30 Apr 2019 Biomarkers information updated
- 22 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Mar 2012 Planned end date changed from 1 Jan 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.